0001209191-21-015471.txt : 20210301 0001209191-21-015471.hdr.sgml : 20210301 20210301200033 ACCESSION NUMBER: 0001209191-21-015471 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210226 FILED AS OF DATE: 20210301 DATE AS OF CHANGE: 20210301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Taylor Stacy L CENTRAL INDEX KEY: 0001799081 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 21700613 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1551 EASTLAKE AVENUE E SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-26 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001799081 Taylor Stacy L C/O ADAPTIVE BIOTECHNOLOGIES 1551 EASTLAKE AVE E STE 200 SEATTLE WA 98102 0 1 0 0 SVP and General Counsel Common Stock 2021-02-26 4 M 0 1041 7.80 A 2341 D Common Stock 2021-02-26 4 M 0 1771 6.55 A 4112 D Common Stock 2021-02-26 4 S 0 1079 54.47 D 3033 D Common Stock 2021-02-26 4 S 0 400 55.46 D 2633 D Common Stock 2021-02-26 4 S 0 1333 56.40 D 1300 D Stock Option (Right to Buy) 7.80 2021-02-26 4 M 0 1041 0.00 D 2029-04-23 Common Stock 1041 27084 D Stock Option (Right to Buy) 6.55 2021-02-26 4 M 0 1771 0.00 D 2028-04-24 Common Stock 1771 23021 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $54.00 to 54.855, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.025 to 55.66, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.01 to 56.66, inclusive. The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. /s/ Stacy L. Taylor by Eric Billings as attorney-in-fact 2021-03-01